Everything below concerns cyclic heptapeptide. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-11-19. Numbers and descriptions here follow the published literature rather than marketing material.
Melanotan-2 is a synthetic cyclic heptapeptide designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous tridecapeptide that regulates pigment production. Two modifications distinguish it from the natural hormone: norleucine replaces methionine at the N-terminus, which limits oxidation, and a D-phenylalanine substitution raises receptor affinity. The ring is closed through an aspartate-lysine lactam bridge, giving the molecule a constrained conformation. The free base has a molecular mass near 1024 daltons, and commercial material is usually supplied as an acetate salt. It appears in the literature as a research peptide rather than an approved therapeutic agent.
Receptor studies place melanotan-2 among non-selective melanocortin agonists, binding MC1R, MC3R, MC4R and MC5R rather than a single subtype. Activation of MC1R on cutaneous melanocytes raises tyrosinase activity and shifts pigment synthesis toward eumelanin, which is darker and more photostable than pheomelanin. Central receptors, particularly MC4R, are associated with appetite suppression and with reported effects on sexual function. Because subtype selectivity is low, the same molecule engages pigment, metabolic and vascular pathways at once, and this breadth is a common explanation offered for the range of adverse events described in user reports.
No regulatory authority has approved melanotan-2 for human use, and several countries classify it as a prescription-only or controlled substance, which restricts lawful supply. Material sold online is generally labelled as a research chemical and is not required to meet pharmaceutical standards of identity or purity. Published human data consist mainly of small uncontrolled studies, case reports and adverse-event notifications, so the evidence base is descriptive rather than confirmatory. Whether repeated melanocyte stimulation alters long-term naevus behaviour remains an open question that no completed trial has resolved.
Melanotan II holds no marketing authorisation from the Food and Drug Administration, the European Medicines Agency, the UK Medicines and Healthcare products Regulatory Agency or Australia's Therapeutic Goods Administration. Products sold under that name are treated as unapproved new drugs, and their sale or import is prohibited in several jurisdictions. Other countries classify the peptide as a prescription-only medicine or place it among controlled substances, so the legal position changes with the destination market. No pharmacopoeial monograph supplies an official specification, because the material is not a licensed pharmaceutical. Consequently, products offered online are not manufactured to a shared public standard.
The peer-reviewed record is dominated by small early-phase studies, case reports and pharmacovigilance summaries rather than large randomised trials. Papers typically examine tanning response, receptor selectivity or patterns of reported adverse events. Many note that participants obtained the peptide outside a clinical setting, which limits verification of composition and administered amount. Reported events vary widely, and causality is frequently unclear because the identity and purity of self-sourced material are unknown. Open questions include whether repeated melanocortin receptor stimulation produces cumulative effects, and how often label claims match actual content.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C50H69N15O9 | Free base; salt forms add to total mass |
| Molecular mass | About 1024 daltons | Calculated for the free base |
| Structural class | Cyclic heptapeptide | Contains D-phenylalanine and norleucine |
| Parent hormone | Alpha-melanocyte-stimulating hormone | Endogenous tridecapeptide of 13 residues |
| Receptor profile | Non-selective melanocortin agonist | Interacts with MC1R, MC3R, MC4R and MC5R |
Melanotan II is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its structure substitutes a lactam bridge between side chains to increase stability relative to the native hormone. The compound is also known by the shorthand MT-II and by several non-proprietary synonyms used in research catalogues. It is not an approved therapeutic product in any major jurisdiction; material sold under this name is typically offered as a laboratory reagent rather than as a medicine.
Activity is attributed to agonism at melanocortin receptors, particularly MC1R and MC4R. Activation of MC1R on melanocytes increases melanin synthesis, which underlies the reported tanning effect. MC4R engagement in the central nervous system is linked to appetite suppression and to effects on sexual arousal reported in early clinical studies. Those studies were small and were not designed to establish efficacy or long-term safety. Receptor selectivity among the melanocortin subtypes is not absolute, which complicates attribution of any effect to a single pathway.
Melanotan-2 has not received marketing authorisation from major regulatory agencies for any therapeutic indication. Several jurisdictions classify it as a prescription-only medicine or a controlled substance when supplied for human use. Because approved products do not exist, material sold online usually sits outside pharmaceutical supply chains and formal quality oversight. Regulators have issued public notices describing the compound as unapproved. Enforcement varies, and the legal position differs between countries, which complicates any single general statement about its status.
Scientific discussion of Melanotan-2 spans pharmacology, dermatology, and public-health literature. Laboratory studies examine its receptor binding and cellular effects, while clinical reports describe outcomes observed after unregulated use. These two bodies of work differ in rigour and intent. Peer-reviewed trials of the compound as a medicine are limited, so much of the available information comes from case reports and surveillance data. Authors frequently note the gap between experimental findings and real-world use.
Melanotan II is a synthetic peptide analog modeled on alpha-melanocyte-stimulating hormone, a naturally occurring signaling peptide involved in pigmentation. Its structure is a cyclic heptapeptide containing two non-natural substitutions, norleucine at position four and D-phenylalanine at position seven. These modifications resist enzymatic breakdown and extend the molecule's activity relative to the native hormone. The compound binds melanocortin receptors and is studied mainly as a pharmacological tool rather than a therapeutic product. It has never received approval as a medicine in any major jurisdiction.
The compound was developed in the late 1980s and 1990s by academic researchers investigating photoprotection. The rationale held that stimulating melanin production might reduce ultraviolet damage to skin and lower skin cancer risk. Early work examined receptor binding, pigment response, and short-term tolerability in small studies. That program did not produce an approved drug, and formal development stalled after early-phase trials. Whether induced pigmentation confers meaningful photoprotection remains an open question.
chromosome A nuclear DNA molecule containing part or all of the genetic material of an organism. Chromosomes may be considered a sort of molecular "package" for carrying DNA within the nucleus of cells and, in most eukaryotes, are composed of long strands of DNA coiled with packaging proteins which bind to and condense the strands to prevent them from becoming an unmanageable tangle. Chromosomes are most easily distinguished and studied in their completely condensed forms, which only occur during cell division. Some simple organisms have only one chromosome made of circular DNA, while most eukaryotes have multiple chromosomes made of linear DNA.
After World War II, democratic socialist, labourist and social-democratic governments introduced social reforms and wealth redistribution via welfare state social programmes and progressive taxation. Those parties dominated post-war politics in the Nordic countries and countries such as Belgium, Czechoslovakia, France, Italy and the United Kingdom. At one point, France claimed the world's most state-controlled capitalist country, starting a period of unprecedented economic growth known as the Trente Glorieuses, part of the post-war economic boom set in motion by the Keynesian consensus. The public utilities and industries nationalised by the French government included Air France, the Bank of France, Charbonnages de France, Électricité de France, Gaz de France and Régie Nationale des Usines Renault. Outside Europe, the Japan Socialist Party was briefly in power in 1947. In 1945, the British Labour Party led by Clement Attlee was elected to office based on a radical, democratic socialist programme. The Labour government nationalised major public utilities and industries such as mining, gas, coal, electricity, rail, iron, steel and the Bank of England. BP was nationalised in 1951. In 1956, Anthony Crosland stated that at least 25% of British industry was nationalised and that public employees, including those in nationalised industries, constituted a similar proportion of the country's total workforce. The 1964–1970 and 1974–1979 Labour governments strengthened the policy of nationalisation.
Basic diagnostic medical devices (e.g., stethoscope, tongue depressor) are typically used. After examining for signs and interviewing for symptoms, the doctor may order medical tests (e.g., blood tests), take a biopsy, or prescribe pharmaceutical drugs or other therapies. Differential diagnosis methods help to rule out conditions based on the information provided. During the encounter, properly informing the patient of all relevant facts is an important part of the relationship and the development of trust within the context of the doctor-patient relationship. The medical encounter is then documented in the medical record, which is a legal document in many jurisdictions. Follow-up encounters may be shorter but follow the same general procedure, and specialists follow a similar process. The diagnosis and treatment may take only a few minutes or a few weeks, depending on the complexity of the issue. The components of the medical interview and encounter are:
Sources: en.wikipedia.org
Peukert argued there was a disconnect between the popular image today of the Nazi era as a time of unparalleled horror vs. the way in which most ordinary Germans remembered it as a time of benign "normality", and that studying Alltagsgeschichte would explore what the Third Reich was actually like in "everyday life". In the early 1980s, Alltagsgeschichte exploded in popularity in West Germany with numerous work groups being set, usually by left-wing groups, to explore the history of their home towns in the Nazi era. The study of Alltagsgeschichte was greatly influenced by the History Workshop movement in Britain set up by the Marxist historian E.P. Thompson and like the British Workshop groups, many involved in the Alltagsgeschichte study groups were not historians with a disproportional number of the volunteers being high-school students. The American historian Mary Nolan wrote with some envy about the way in which thousands of German high school students became involved in the Alltagsgeschichte study groups, observing that it was simply inconceivable that thousands of American high school students would join study groups to research the histories of their home towns in the 1930s-1940s as most Americans have no interest in history. In 1984, Peukert was awarded the annual culture prize given by the city of Essen for his work with a history workshop group in Essen.
The English name of "Singapore" is an anglicisation of the native Malay name for the country, Singapura (Malay pronunciation: [siŋapura] ), which was in turn derived from the Sanskrit word for 'lion city' (Sanskrit: सिंहपुर; romanised: Siṃhapura; Brahmi: 𑀲𑀺𑀁𑀳𑀧𑀼𑀭; literally "lion city"; siṃha means 'lion', pura means 'city' or 'fortress'). Pulau Ujong was one of the earliest names for the island of Singapore, which corresponds to a Chinese account from the third century referred to a place as Pú Luó Zhōng (Chinese: 蒲 羅 中), a transcription of the Malay name for 'island at the end of a peninsula'. Early references to the name Temasek (or Tumasik) are found in the Nagarakretagama, a Javanese eulogy written in 1365, and a Vietnamese source from the same time period. The name possibly means Sea Town, being derived from the Malay tasek, meaning 'sea' or 'lake'. The Chinese traveller Wang Dayuan visited a place around 1330 named Danmaxi (Chinese: 淡馬錫; pinyin: Dànmǎxí; Wade–Giles: Tan Ma Hsi) or Tam ma siak, depending on pronunciation; this may be a transcription of Temasek, alternatively, it may be a combination of the Malay Tanah meaning 'land' and Chinese xi meaning 'tin', which was traded on the island. Variations of the name Siṃhapura were used for a number of cities throughout the region prior to the establishment of the Kingdom of Singapura. In Hindu–Buddhist culture, lions were associated with power and protection, which may explain the attraction of such a name.
=== Other related diseases === Cholera Enteric duplication cyst Giardiasis Pancreatitis Peptic ulcer disease Yellow fever Helicobacter pylori is a gram-negative spiral bacterium. Over half the world's population is infected with it, mainly during childhood; it is not certain how the disease is transmitted. It colonizes the gastrointestinal system, predominantly the stomach. The bacterium has survival conditions that are specific to the human gastric microenvironment: it is both capnophilic and microaerophilic. Helicobacter also exhibits a tropism for gastric epithelial lining and the gastric mucosal layer about it. Gastric colonization of this bacterium triggers a robust immune response leading to moderate to severe inflammation, known as gastritis. Signs and symptoms of infection are gastritis, burning abdominal pain, weight loss, loss of appetite, bloating, burping, nausea, bloody vomit, and black tarry stools. Infection can be detected in a number of ways: GI X-rays, endoscopy, blood tests for anti-Helicobacter antibodies, a stool test, and a urease breath test (which is a by-product of the bacteria). If caught soon enough, it can be treated with three doses of different proton pump inhibitors as well as two antibiotics, taking about a week to cure. If not caught soon enough, surgery may be required. Intestinal pseudo-obstruction is a syndrome caused by a malformation of the digestive system, characterized by a severe impairment in the ability of the intestines to push and assimilate.
Sources: en.wikipedia.org
No regulatory agency has authorised melanotan-2 as a medicine for any indication. It circulates mainly as a research chemical or through unregulated channels. As a result, identity, purity and content are not independently guaranteed.
Melanotan-1, also called afamelanotide, is a linear analogue with greater selectivity for MC1R and has received approval in some jurisdictions for a specific photosensitivity disorder. Melanotan-2 is cyclic, less selective, and reaches central receptors more readily. The two are often confused in online discussion despite different pharmacology and regulatory status.
Alpha-MSH is an endogenous tridecapeptide derived from pro-opiomelanocortin. Melanotan-2 reproduces its core receptor-binding sequence inside a shortened, stabilised ring. The result is a molecule with a longer effective half-life and higher potency than the parent hormone.
Regulatory treatment varies by country. In the United States, the European Union and Australia it is an unapproved drug and its sale is restricted, while some other jurisdictions list it as prescription-only or controlled. The applicable rules depend on the country of import.